Sign In
Free Newsletter
Md. biopharm gets 2 new neurodegenerative disorder treatment patents
Neuralstem Inc., a Germantown biopharmaceutical company working on treatments for nervous system diseases, was awarded two patents by the U.S. Patent and Trademark Office. One patent covers ways of treating […]
Md. biopharm gets $1M NIH grant to study drug
Neuralstem Inc., a biopharmaceutical company, recently received a grant worth up to nearly $1 million from the National Institutes of Health. The Germantown company received the research grant, to evaluate over two years […]
As stock falls, Md. biopharm aims to raise under $6m in stock offering
Germantown-based Neuralstem Inc., a biopharmaceutical firm developing treatments for nervous system diseases on Thursday announced plans to raise less than $6 million through an underwritten public offering. Neuralstem will offer 3 million shares […]
Md. biopharm’s antidepressant has mixed results in clinical trial
A Maryland biopharmaceutical company on Tuesday announced mixed results for its phase 2 clinical trial of its experimental antidepressant. The study, by Germantown-based Neuralstem Inc. of its NSI-189 drug, given once […]
Fortuitious find helps Neuralstem win dismissal of claim
Neuralstem Inc. can thank the discovery of a 1991 agreement among three inventors for a federal judge’s dismissal Wednesday of a multimillion-dollar claim that the Germantown-based biotech company infringed a California firm’s patent on a spinal treatment.
Neuralstem posts bigger loss
Neuralstem, of Germantown, a biotechnology company that produces stem-cell treatments for central nervous system diseases and conditions, reported a bigger loss for 2014 than in 2013. Neuralstem posted a net […]
Neuralstem loss lower in quarter
Neuralstem Inc., a Germantown-based biotechnology company, narrowed its loss in the third quarter. Neuralstem reported a net loss of $4.5 million, or 5 cents per share, compared with $6.7 million, […]
Neuralstem Phase I trial starts in San Diego
Neuralstem Inc., of Germantown, a biotechnology company, announced that the first patient was treated last week in the Phase I trial testing its NSI-566 human neural stem cells for chronic […]
Neuralstem completes sale of stock
Neuralstem Inc., of Rockville, which develops products to treat central nervous system disorders with patented stem cell technology, announced the closing of a $20 million registered direct placement of approximately 6.87 million shares of common stock at a price of $2.91 per share.
Rockville-based Neuralstem reports higher 2Q loss
Neuralstem Inc., of Rockville, a biotherapeutic company developing products to treat central nervous system disorders with patented stem cell technology, reported a second-quarter net loss of $6.25 million, or 9 cents per share, compared to a net loss of $2.5 million, or 4 cents per share, in the prior-year period.
Study boosts Neuralstem product
One of Neuralstem Inc.’s products was shown to improve function after a spinal cord injury in a study among rats.
FDA OKs Neuralstem’s ALS clinical trial
Neuralstem Inc., of Rockville, a biotherapeutic company developing products to treat central nervous system disorders with patented stem cell technology, said it received approval from the Food and Drug Administration to begin a Phase II trial using spinal cord-derived human neural stem cells to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
